ALX Oncology Holdings Inc. (ALXO)
ALXO moved a median of +0.10% 30 minutes after news, and 0.00% by the close. How ALXO actually reacts to news — the realized, point-in-time move the market made, measured across 280 labeled events over the last three years with zero look-ahead.
ALXO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 42% | 279 |
| 30-min | +0.10% | 50% | 280 |
| 60-min | +0.03% | 50% | 280 |
| to close | 0.00% | 48% | 278 |
| Middle 50% of ALXO reactions | -2.78% to +2.04% |
|---|---|
| Median reaction (30-min) | +0.10% |
| Measured reactions | 280 |
Half of all ALX Oncology Holdings Inc. news events land between -2.78% and +2.04% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ALXO reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 12 | -0.32% | 33% | -0.41% |
| Rating reiterations | 46 | -0.28% | 28% | -3.45% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how ALXO ranks against every other measured name →
That’s how ALXO usually reacts — get an email when it moves on news →Email me when ALXO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ALXO's baseline. Nothing else.
Recent ALXO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K ALX ONCOLOGY HOLDINGS For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | -3.27% | +6.00% | |
| ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer | Press release | GlobeNewswire | +1.14% | +5.30% | |
| ALX Oncology to Present at Upcoming Investor Conferences in September | Press release | GlobeNewswire | +2.02% | +5.05% | |
| ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -2.01% | +8.76% | |
| Form 10-Q ALX ONCOLOGY HOLDINGS For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.90% | -0.47% | |
| Form 8-K ALX ONCOLOGY HOLDINGS For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | -2.01% | +8.76% | |
| ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel | Press release | GlobeNewswire | -0.68% | -6.76% | |
| ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules | Press release | GlobeNewswire | +0.05% | +0.98% | |
| Form 8-K ALX ONCOLOGY HOLDINGS For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | +0.05% | +0.98% | |
| Form 8-K ALX ONCOLOGY HOLDINGS For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | -0.75% | +10.00% | |
| Form 8-K ALX ONCOLOGY HOLDINGS For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +3.95% | |
| ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York | Press release | GlobeNewswire | -2.12% | -4.76% | |
| ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -1.59% | +10.05% | |
| Form 10-Q ALX ONCOLOGY HOLDINGS For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.59% | +10.05% | |
| Form 8-K ALX ONCOLOGY HOLDINGS For: May 08 | SEC filing · Form 8-K | SEC EDGAR | -1.59% | +10.05% | |
| ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression | Press release | GlobeNewswire | -2.54% | -10.53% | |
| ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026 | Press release | GlobeNewswire | +0.94% | +6.92% | |
| Form ARS ALX ONCOLOGY HOLDINGS For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -3.39% | -3.96% | |
| Form DEF 14A ALX ONCOLOGY HOLDINGS For: Apr 17 | SEC filing · Form DEF | SEC EDGAR | -3.39% | -3.96% | |
| ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules | Press release | GlobeNewswire | +0.60% | +4.79% | |
| ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer | Press release | GlobeNewswire | +0.32% | +4.17% | |
| Form 8-K ALX ONCOLOGY HOLDINGS For: Apr 13 | SEC filing · Form 8-K | SEC EDGAR | +0.32% | +4.17% | |
| Form 10-K ALX ONCOLOGY HOLDINGS For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.83% | — | |
| ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -6.02% | -2.31% | |
| Form 8-K ALX ONCOLOGY HOLDINGS For: Feb 27 | SEC filing · Form 8-K | SEC EDGAR | -6.02% | -2.31% | |
| ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026 | Press release | GlobeNewswire | -2.15% | +11.59% | |
| ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 | Press release | GlobeNewswire | -2.15% | +11.59% | |
| ALX Oncology Announces Pricing of Underwritten Offering | Press release | GlobeNewswire | +8.31% | -1.14% | |
| Form 8-K ALX ONCOLOGY HOLDINGS For: Jan 30 | SEC filing · Form 8-K | SEC EDGAR | +8.31% | -1.14% | |
| New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer | Press release | GlobeNewswire | +8.31% | -1.14% | |
| Form 8-K ALX ONCOLOGY HOLDINGS For: Jan 21 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.68% | |
| Form S-8 ALX ONCOLOGY HOLDINGS | SEC filing · Form S-8 | SEC EDGAR | +0.00% | -0.68% | |
| ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004 | Press release | GlobeNewswire | +3.81% | +5.08% | |
| ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | — | -0.80% | |
| ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting | Press release | GlobeNewswire | +0.01% | -6.49% | |
| ALX Oncology to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | -0.14% | +5.16% | |
| ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.01% | +14.05% | |
| Form 10-Q ALX ONCOLOGY HOLDINGS For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.79% | +0.00% | |
| Form 8-K ALX ONCOLOGY HOLDINGS For: Nov 07 | SEC filing · Form 8-K | SEC EDGAR | +0.01% | +14.05% | |
| ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting | Press release | GlobeNewswire | +0.32% | -1.27% | |
| ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference | Press release | GlobeNewswire | -0.28% | -0.57% | |
| ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting | Press release | GlobeNewswire | +0.60% | +13.54% | |
| ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer | Press release | GlobeNewswire | -3.39% | -10.17% | |
| Form 8-K ALX ONCOLOGY HOLDINGS For: Sep 11 | SEC filing · Form 8-K | SEC EDGAR | -3.39% | -10.17% | |
| ALX Oncology to Participate in Upcoming Investor Conferences in September | Press release | GlobeNewswire | -0.44% | +3.54% | |
| ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors | Press release | GlobeNewswire | +4.99% | — | |
| ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -0.18% | +6.55% | |
| Form 10-Q ALX ONCOLOGY HOLDINGS For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.18% | +6.55% | |
| Form 8-K ALX ONCOLOGY HOLDINGS For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | -0.18% | +6.55% | |
| ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025 | Press release | GlobeNewswire | -3.26% | +15.23% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ALXO section they belong to.
Where else ALXO is measured.
ALXO earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is ALX Oncology Holdings Inc.'s median reaction calculated?
Every labeled ALXO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 280 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of ALXO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ALXO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.